Not logged in Share Save
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer Shore, Neal; Pieczonka, Christopher; Heron, Sean; Gazi, Mukaram; Cahn, David; Belkoff, Laurence H.; Berger, Aaron; Mazzarella, Brian; Veys, Joseph; Idom, Charles; Morris, David; Jayram, Gautam; Engelman, Alexander; Dato, Paul; Bevan-Thomas, Richard; Wise, David R.; Hardwick, Mary Kay; Rojahn, Susan; Layman, Paige; Heald, Brandie; Ellsworth, Rachel E.; Hatchell, Kathryn E.; Nussbaum, Robert L.; Nielsen, Sarah M.; Esplin, Edward D. Share Save
Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210 Guerrero-Ramos, F.; Ku, J. H.; Vilaseca, A.; Raventos, C. X.; Shore, N. D.; Meeks, J.; Li, R.; Daneshmand, S.; Jayram, G.; Kang, T. W.; Beeharry, N.; Zhang, J.; Weingeist, D.; Smirnov, D. A.; Brunton, B.; Cost, C.; Kalota, A.; Lauring, J.; Stone, N.; Thomas, S. Share Save
First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non emuscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt) Vilaseca, A.; Jayram, G.; Raventos, C.; Shore, N. D.; Zainfeld, D.; Kang, T. W.; Ku, J. H.; Meeks, J.; Faba, O. Rodriguez; Roghmann, F.; Daneshmand, S.; Beeharry, N.; Cost, C.; Kalota, A.; Lauring, J.; Peterson, M.; Quiroz, M.; Stone, N.; Zhu, W.; Guerrero-Ramos, F. Share Save
Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial Shore, Neal; Gazi, Mukaram; Pieczonka, Christopher; Heron, Sean; Modh, Rishi; Cahn, David; Belkoff, Laurence H.; Berger, Aaron; Mazzarella, Brian; Veys, Joseph; Idom, Charles; Morris, David; Jayram, Gautam; Engelman, Alexander; Bukkapatnam, Raviender; Dato, Paul; Bevan-Thomas, Richard; Cornell, Robert; Wise, David R.; Hardwick, Mary Kay; Hernandez, Ryan D.; Rojahn, Susan; Layman, Paige; Hatchell, Kathryn E.; Heald, Brandie; Nussbaum, Robert L.; Nielsen, Sarah M.; Esplin, Edward D. Share Save
Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study Gratzke, C. J.; Ozguroglu, M.; Peer, A.; Sendur, M. A. N.; Retz, M.; Goh, J. C. H.; Loidl, W. C.; Jayram, G.; Byun, S-S.; Kwak, C.; Kwiatkowski, M.; Kopp, R. Manneh; Limon, J. C. Vazquez; Penagos, J. F. Escobar; De Giorgi, U. F. F.; Trindade, K. M. D.; Niu, C.; Liu, Y.; Poehlein, C. H.; Rodriguez, J. M. Piulats Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Not logged in.png){kind=icon}